Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TEAD1–4 mRNAs are the messenger RNA transcripts encoding the TEA Domain (TEAD) family of transcription factors, which serve as the primary nuclear effectors of the Hippo signaling pathway. In healthy cells, the Hippo pathway regulates organ size and tissue homeostasis by modulating the activity of co-activators YAP and TAZ, which bind to TEAD proteins to drive the expression of genes involved in cell proliferation and survival. In many cancers, particularly those with NF2 mutations or YAP/TAZ overactivation, the TEAD transcription complex becomes constitutively active, driving oncogenesis and drug resistance. Targeting the TEAD1–4 mRNAs using antisense oligonucleotides (ASOs) or RNA interference (RNAi) aims to reduce the cellular pool of TEAD proteins, thereby dismantling the transcriptional machinery required for tumor growth. This approach is currently being explored in clinical settings, with a focus on mesothelioma and other Hippo-deficient solid tumors where TEAD activity is a critical driver.
Antisense oligonucleotide-mediated degradation of mRNA, RNA interference (siRNA), inhibition of translation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcriptional enhancer factor TEAD1–4 messenger RNA (TEAD1–4 mRNA).